Table 1.

Respondent Demographics, Disease Categorization, Treatment, and Vaccine Received.

Demographic	Respondents (%)
Total responses	1218
Complete responses	964
Gender
Male	254 (26.4)
Female	707 (73.4)
Trans male	1 (0.1)
Trans female	0 (0.0)
Other	1 (0.1)
Age
16–24	2 (0.2)
25–35	25 (2.6)
36–45	104 (10.8)
46–59	299 (31.0)
60–69	322 (33.4)
70–75	136 (14.1)
76 or older	76 (7.9)
Ethnicity
White—English, Welsh, Scottish, Northern Irish, or British	816 (84.7)
White—Irish	38 (4.0)
White—any other	71 (7.3)
Mixed or multiple ethnic groups—White and Black African	2 (0.2)
Mixed or multiple ethnic groups—White and Asian	2 (0.2)
Mixed or multiple ethnic groups—any other	2 (0.2)
Asian or Asian British—Indian	3 (0.3)
Asian or Asian British—Pakistani	1 (0.1)
Asian or Asian British—Chinese	2 (0.2)
Asian or Asian British—any other	7 (0.7)
Black, African, Caribbean, or Black British—African	4 (0.4)
Black, African, Caribbean, or Black British—Caribbean	6 (0.6)
Black, African, Caribbean, or Black British—any other	1 (0.1)
Other ethnic group—any other	6 (0.6)
Prefer not to answer	2 (0.2)
Country
England	764 (79.2)
Scotland	68 (7.0)
Wales	33 (3.4)
Northern Ireland	12 (1.2)
Republic of Ireland	16 (1.7)
Other	54 (5.6)
Prefer not to answer	17 (1.8)
Diagnosis
Polycythaemia vera (PV)	270 (28.0)
Essential thrombocythemia (ET)	548 (56.9)
Primary myelofibrosis (MF)	42 (4.4)
Post-ET myelofibrosis	39 (4.0)
Post-PV myelofibrosis	29 (3.0)
Prefibrotic myelofibrosis	7 (0.7)
MPN—unclassified	16 (1.7)
Other	13 (1.4)
Current treatment
Observation	134 (15.2)
Venesection	111 (12.6)
Hydroxycarbamide	437 (49.7)
Interferon	23 (2.6)
Pegylated interferon A	101 (11.5)
Anagrelide	26 (3.0)
Ruxolitinib	83 (4.4)
Busulfan	2 (0.2)
Other	103 (11.7)
Vaccine received
AstraZeneca (ChAdOx1-S [recombinant])	457 (51.8)
Pfizer/BioNTech (BNT162b2)	414 (46.9)
Moderna (mRNA-1273)	10 (1.1)
Johnson & Johnson (JNJ-78436735)	1 (0.1)